X
LCTX icon

Xponance’s Lineage Cell Therapeutics LCTX Stock Holding History

Xponance’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23K Buy
+17,522
New +$24.2K ﹤0.01% 1828
2025
Q2 		– Sell
-12,875
Closed -$5.81K – 1526
2025
Q1 		$5.81K Buy
12,875
+2,419
+23% +$1.42K ﹤0.01% 1444
2024
Q4 		$5.25K Buy
+10,456
New +$7.68K ﹤0.01% 1443

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Xponance's LCTX Position: Q2 2026 in Review

Xponance opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 17,522 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #1828 among its holdings. This is a return to the name: Xponance previously reported a position in LCTX as recently as Q1 2025.

Xponance first reported a position in LCTX in Q4 2024 and has held it in 3 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Xponance held 17,522 shares of Lineage Cell Therapeutics worth $23K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Xponance position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1828 holding.
  • Xponance first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.